Press Coverage
PI decision at UPC local division Munich after withdrawal of the PI request
The article sheds light on preliminary injunction proceedings before the local division of the Unified Patent Court (UPC) in Munich between the applicant Tiroler Rohre (TRM) and the defendants SSAB Swedish Steel GmbH and SSAB Europe Oy concerning pile shoes for anchoring str...
Continue reading
Generic drug companies attack Novo Nordisk’s diabetes and weight-loss drug
Generic drug companies have successfully challenged two key Novo Nordisk patents related to the tablet formulation of semaglutide, a blockbuster drug for diabetes (Rybelsus) and weight loss (Wegovy). The European Patent Office’s Boards of Appeal revoked patents EP 2 827 84...
Continue reading
Sanofi cabazitaxel patent revoked by Paris court
In the ongoing case between Sanofi and the generic drug manufacturer Accord, the Paris Judicial Court has fully revoked Sanofi’s patent for the chemotherapy drug Jevtana. The patent EP 2 493 466, which protects a new use of cabazitaxel in combination with prednisone or pre...
Continue reading
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
Deal provides Cytokinetics with diversified access to capital as company advances its specialty cardiology franchise NEW YORK, NY and SOUTH SAN FRANCISCO, CA, May 22, 2024 – Royalty Phar...
Continue reading
Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
Frexalimab is in Phase 3 development by Sanofi in multiple sclerosis with multi-blockbuster potential in a wide range of immune-mediated diseases Expands Royalty Pharma’s ...
Continue reading
The UPC has become known for its expeditious decision-making processes
The UPC has become known for its expeditious decision-making processes. Just how expeditious it can be, has been shown in a recent case filed with the Munich local division against one of our clients. After a quick review of the claimant’s statement of claim, we infor...
Continue reading
